Ascending single-dose study of the safety, pharmacokinetics, and pharmacodynamics of CSTI-500, a novel monoamine triple reuptake inhibitor, first-in-human.

Rationale: Monoamine triple reuptake inhibitors (TRIs) inhibit central dopamine, norepinephrine, and serotonin transporters, restoring functional monoamine neurotransmission. Objectives: This clinical trial evaluated the safety, tolerability, and pharmacokinetics in healthy volunteers after single-a...

Full description

Bibliographic Details

Published in:	Psychopharmacology Vol. 243; no. 3; pp. 565 - 581
Main Authors:	Appel, Lieuwe, Risinger, Robert, Wall, Anders, Murck, Harald, Liu, Shuang, Antoni, Gunnar, Lane, Roger
Format:	Journal Article
Published:	Springer Nature Mar2026
Online Access:	View this record in EBSCOhost